Neues FIGO-Staging-System für Sarkome des Uterus-Reference-Cited by-同舟云学术

Neues FIGO-Staging-System für Sarkome des Uterus

Published:2009-06-05 Issue:4 Volume:30 Page:302-303
ISSN:0172-8113
Container-title:Der Pathologe
language:de
Short-container-title:Pathologe

Author:

Horn L.-C., ,Schmidt D.,Fathke C.,Ulrich U.

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00292-009-1158-8.pdf

Reference8 articles.

1. FIGO (1989) Announcements, FIGO stages: 1988 Revision. Gynecol Oncol 35:125

2. FIGO Committee on Gynecologic Oncology (2009) FIGO staging for uterine sarcomas. Int J Gynaecol Obstet 104:179

3. Hendrickson MR, Tavassoli FA, Kempson RL et al (2003) Mesenchymal tumors of the uterus and related lesions. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs. World Health Organization Classification of Tumours. IARC Press, Lyon, pp 233–249

4. Horn LC, Dallacker M, Bilek K (2009) Karzinosarkome (maligne Müller-Mischtumoren) des Uterus: Morphologie, molekulare Pathogenese und morphologische Prognosefaktoren. Pathologe (gleiches Heft)

5. McCluggage WG (2002) Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 55(5):321–325

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of tumor morcellation in patients with early uterine sarcoma: a multicenter study in Germany;Journal of the Turkish-German Gynecological Association;2022-05-31

2. HPV51-associated Leiomyosarcoma;American Journal of Surgical Pathology;2022-01-17

3. CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion;JCO Precision Oncology;2020-11

4. CDKN2C homozygous loss identifies a distinct subtype of TP53/RB1-wildtype leiomyosarcoma with frequent CIC genomic alterations and 1p/19q-codeletion;2020-03-04

5. Extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 overexpression is associated with loss of hormone receptor expression and poor prognosis in endometrial cancer;Oncology Letters;2015-05-06